By

Arup Das MD, PhD, Professor of Ophthalmology, University of New Mexico, Albuquerque, NM
Thomas Friberg MS, MD, Professor of Ophthalmology, The Ear and Eye Institute of Pittsburgh, Pittsburgh, PA

Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. In addition, retinal and choroidal neovascularization are the major causes of vision loss in this country. With the new era of anti-angiogenic therapies already in practice, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs.

Therapy for Ocular Angiogenesis: Principles and Practice covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the “Principles” of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the “Practice” of the therapy in many ocular diseases. Vision researchers in both academia and industry, as well as clinician scientists, have contributed chapters on different aspects of the angiogenic process, and clinical strategies to fight it. The book also includes chapters that deal with diabetic macular edema, and various therapeutic options for this condition.

A companion website includes the fully searchable text and an image bank.

Key Features

Discusses the principles of angiogenesis therapies and pathophysiology of ocular angiogenesis.
Summarizes the clinical trials that led to approval of two FDA approved drugs in the field.
Discusses ongoing clinical trials in the field.
Describes potential new anti-angiogenesis drugs in the horizon.
Discusses different drug delivery approaches in the eye.